Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian J Moran

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
International Journal of Radiation Oncology, Biology, Physics|September 28, 2011
Type of diabetes mellitus and the odds of Gleason score 8 to 10 prostate cancerJosephine Kang, Ming-Hui Chen, Yuanye Zhang, et al.
The Journal of Urology|May 17, 2011
Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk diseaseNils D Arvold, Ming-Hui Chen, Judd W Moul, et al.
BJU International|March 17, 2010
Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or strokeJulia H Hayes, Ming-Hui Chen, Brian J Moran, et al.
International Journal of Radiation Oncology, Biology, Physics|October 30, 2016
Androgen Deprivation Therapy Use in the Setting of High-dose Radiation Therapy and the Risk of Prostate Cancer-Specific Mortality Stratified by the Extent of Competing MortalityBrent S Rose, Ming-Hui Chen, Jing Wu, et al.
American Journal of Clinical Oncology|January 29, 2011
ACR appropriateness criteria postradical prostatectomy irradiation in prostate cancerCarl J Rossi, I-Chow Joe Hsu, May Abdel-Wahab, et al.
International Journal of Radiation Oncology, Biology, Physics|February 4, 2012
The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selectionDaniel A Wattson, Ming-Hui Chen, Judd W Moul, et al.
Brachytherapy|December 14, 2005
Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysisGregory S Merrick, Wayne M Butler, Kent E Wallner, et al.
Journal of the American College of Radiology : JACR|April 4, 2012
ACR Appropriateness Criteria® external-beam radiation therapy treatment planning for clinically localized prostate cancerMay Abdel-Wahab, Omar Mahmoud, Gregory Merrick, et al.
International Journal of Radiation Oncology, Biology, Physics|June 6, 2006
Comparison of biochemical failure definitions for permanent prostate brachytherapyDeborah A Kuban, Larry B Levy, Louis Potters, et al.
Urologic Oncology|December 26, 2017
Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancerMartin T King, Ming-Hui Chen, Brian J Moran, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
International Journal of Radiation Oncology, Biology, Physics|September 28, 2011
Type of diabetes mellitus and the odds of Gleason score 8 to 10 prostate cancerJosephine Kang, Ming-Hui Chen, Yuanye Zhang, et al.
The Journal of Urology|May 17, 2011
Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk diseaseNils D Arvold, Ming-Hui Chen, Judd W Moul, et al.
BJU International|March 17, 2010
Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or strokeJulia H Hayes, Ming-Hui Chen, Brian J Moran, et al.
International Journal of Radiation Oncology, Biology, Physics|October 30, 2016
Androgen Deprivation Therapy Use in the Setting of High-dose Radiation Therapy and the Risk of Prostate Cancer-Specific Mortality Stratified by the Extent of Competing MortalityBrent S Rose, Ming-Hui Chen, Jing Wu, et al.
American Journal of Clinical Oncology|January 29, 2011
ACR appropriateness criteria postradical prostatectomy irradiation in prostate cancerCarl J Rossi, I-Chow Joe Hsu, May Abdel-Wahab, et al.
International Journal of Radiation Oncology, Biology, Physics|February 4, 2012
The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selectionDaniel A Wattson, Ming-Hui Chen, Judd W Moul, et al.
Brachytherapy|December 14, 2005
Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysisGregory S Merrick, Wayne M Butler, Kent E Wallner, et al.
Journal of the American College of Radiology : JACR|April 4, 2012
ACR Appropriateness Criteria® external-beam radiation therapy treatment planning for clinically localized prostate cancerMay Abdel-Wahab, Omar Mahmoud, Gregory Merrick, et al.
International Journal of Radiation Oncology, Biology, Physics|June 6, 2006
Comparison of biochemical failure definitions for permanent prostate brachytherapyDeborah A Kuban, Larry B Levy, Louis Potters, et al.
Urologic Oncology|December 26, 2017
Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancerMartin T King, Ming-Hui Chen, Brian J Moran, et al.
Pageof 6